ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 157 filers reported holding ASCENDIS PHARMA A/S in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $740,712 | -25.4% | 5,881 | -47.1% | 0.00% | -66.7% |
| Q2 2023 | $992,906 | -44.5% | 11,125 | -35.8% | 0.00% | -66.7% |
| Q3 2022 | $1,789,000 | +417.1% | 17,329 | +365.8% | 0.01% | +350.0% |
| Q2 2022 | $346,000 | +40.7% | 3,720 | +103.7% | 0.00% | +100.0% |
| Q4 2021 | $246,000 | -60.5% | 1,826 | -53.3% | 0.00% | -50.0% |
| Q3 2021 | $623,000 | -26.9% | 3,908 | -39.7% | 0.00% | -33.3% |
| Q2 2021 | $852,000 | +74.2% | 6,477 | +104.6% | 0.00% | -57.1% |
| Q3 2020 | $489,000 | +27.0% | 3,166 | -7.4% | 0.01% | -30.0% |
| Q1 2020 | $385,000 | -55.7% | 3,420 | -53.7% | 0.01% | +11.1% |
| Q1 2019 | $869,000 | +326.0% | 7,379 | +126.3% | 0.01% | +350.0% |
| Q4 2018 | $204,000 | -28.7% | 3,260 | -24.2% | 0.00% | -50.0% |
| Q2 2018 | $286,000 | -20.6% | 4,300 | -21.8% | 0.00% | -33.3% |
| Q1 2018 | $360,000 | – | 5,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |